REMS requires patients to administer Spravato at a clinic in the presence of a physician. “We probably know more about the ...

Spravato, a nasal spray containing esketamine, is now subsidized in Australia for adults with treatment-resistant depression who have not responded to at least two other antidepressants.

In fact, the FDA has approved its use through a restricted program known as the Spravato Risk Evaluation and Mitigation Strategy (REMS) program, which allows patients to take the drug only under ...

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide.

Amber Grob provides Esketamine/Spravato treatment in office as well and is registered with the Spravato REMS Program.

I treat adults and children age 5 and up. Our clinic is a Spravato REMS certified treatment center to treat treatment resistant depression. I practice holistically which includes taking into ...

An antidepressant containing a form of the drug ketamine has been added to the Pharmaceutical Benefits Scheme (PBS), making it much cheaper for the estimated 30,000 Australians with treatment ...